1. Pink Sheet
  2. >>Product Reviews

Clinical Study Report Release Could Compromise Patient Privacy, Groups Say

 
• By Derrick Gingery

US FDA's plan to post CSRs may also inadvertently release confidential commercial information, agency is warned by industry groups.

lock security businessman protect concept whistleblower cybersecurity
The FDA redacted data in the clinical study reports, but there was no assurance it was truly anonymized, BIO said. • Source: Shutterstock

The US Food and Drug Administration is releasing information in clinical study reports that could help hackers identify patients, some groups said in formal comments about the idea.

Former Commissioner Scott Gottlieb spearheaded releasing clinical study reports (CSRs), which are scientific documents containing detailed summaries of clinical trial methods and results, as

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 
• By Francesca Bruce

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.